📅 PUBMED DAILY TRIAGE — 2026-06-04
Window: 2026-06-03T09:00:00Z → 2026-06-04T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~85 candidates | Classified: 26 High priority: 4 | Standard: 18 | Low/archive: 4 | Unsolicited finds: 1 Run status: ✅ SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)
TR-2026-06-04-001 / PMID 42235013 · All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia · 9/10 🟢
N Engl J Med · Roboz GJ, Zeidan AM, DiNardo CD et al. (Weill Cornell / Yale / MD Anderson / Taiho Oncology) · Phase 1-2 multicenter trial · n=189 Why it matters: First fully oral regimen (decitabine-cedazuridine + venetoclax) for AML patients ineligible for intensive chemo — achieves 47% CR, 63% CRc, mOS 15.5 months with NO IV/SC administration required. Eliminates parenteral burden for elderly/frail population. Decitabine-cedazuridine already approved in Europe. Near-term practice change pathway exists. ⚠️ Taiho Oncology funded; phase 1-2 nonrandomized (no comparator arm vs aza+ven)
Early Cancer Detection (Liquid Biopsy / ctDNA)
TR-2026-06-04-003 / PMID 42236991 · Prognostic Value of ctDNA-Based MRD for Recurrence-Free Survival in Resectable Gastric Cancer · 8/10 🔴
Dig Dis Sci · Mehboob AA, Khan AU et al. · Systematic review & meta-analysis · 8 studies, n=520 Why it matters: Postoperative ctDNA positivity predicts 12-fold worse RFS (HR 12.26, CI 3.30–45.52) and 8.6-fold worse OS (HR 8.57) in resectable gastric cancer — strongest ctDNA prognostic signal seen in this indication. Serial monitoring adds incremental value over single time-point. Direct implication for adjuvant therapy escalation decisions. ⚠️ Wide CI reflects inter-study heterogeneity; 8 studies only
Precision Oncology / Genomic Medicine
TR-2026-06-04-002 / PMID 42237038 · Tumor Transcriptional State Predicts Survival in ICB-Treated Glioblastoma · 8/10 🟠
Nat Cancer · Ghannam JY, Bryan J, Wu CJ et al. (Dana-Farber / Broad Institute / Weizmann) · Multi-platform translational cohort · n=181 ICB-treated GBM Why it matters: Mesenchymal (MES) transcriptional subtype — not TMB — predicts ICB benefit in GBM. Non-MES genetic lesions (PDGFRA, CDKN2A) associated with worse ICB outcomes. MES-to-non-MES transition identified as acquired resistance trajectory. Directly challenges TMB as GBM ICB biomarker. ⚠️ Multiple COI (Getz: Scorpion Therapeutics; Reardon: multiple advisory boards)
TR-2026-06-04-004 / PMID 42236958 · Single-Cell Spatial Pharmacobiology Identifies Conserved Stromal Barriers to Antibody Delivery in Solid Tumors · 8/10 🟠
Nat Biotechnol · Lu G, Hickey JW, Nolan GP, Rosenthal EL et al. (Stanford) · Translational study using human phase 1 trial samples · HNSCC + PDAC Why it matters: Introduces SSP framework — first in-human single-cell drug delivery mapping via spatial proteomics + fluorescent antibody tracking. Identifies periostin-rich ECM and FAP+ CAF neighborhoods as conserved antibody delivery barriers in both HNSCC and PDAC, providing a mechanistic basis for stromal-targeting combinations. ⚠️ Nolan/Goltsev equity in Akoya Biosciences; evidence_maturity = Exploratory (novel methodology)
🟢⚪ STANDARD (5–7) — Top by Topic
Hematologic Malignancies
- TR-2026-06-04-005 / PMID 42236629 · CACAG-VEN for AML-MR · 7/10 · Treatment Innovation · CR 83.3% vs 55.7% std (n=60 retrospective, single-center)
- TR-2026-06-04-006 / PMID 42235731 · FLT3 mutations as diagnostic/prognostic biomarkers in AML · 6/10 · Diagnostics · Comprehensive lab implementation review
- TR-2026-06-04-007 / PMID 42236165 · PV thromboembolism burden SLR (35 studies) · 6/10 · Public Health · 1.4–6.5 TEs/100pt-yr; ⚠️ Takeda-funded
CBC / ML in Hematology
- TR-2026-06-04-008 / PMID 42231960 · Brain age GNN in beta-thalassemia major children (iScience, n=65) · 6/10 · Diagnostics · Brain age index correlates with Hgb/ferritin; PMC open access; n=25 patients
Early Cancer Detection
- TR-2026-06-04-009 / PMID 42236890 · ctDNA kinetics joint modeling in metastatic breast cancer (NPJ Precis Oncol, n=49) · 6/10 · Diagnostics · Dynamic TF prediction vs OS/TTD; ⚠️ Guardant Health authorship
- TR-2026-06-04-010 / PMID 42237054 · ctDNA review in ovarian cancer (Discov Oncol) · 5/10 · Early Detection · Review; no new primary data
AI/ML in Diagnostics
- TR-2026-06-04-012 / PMID 42236117 · Spatial TNBC immunotype landscape — pDC/IFN signaling (J Immunother Cancer, n=212 + 4 validation cohorts) · 7/10 · Precision Medicine · Immune-excluded TNBC has poor outcomes despite high sTILs; pDCs/IFN predictive across therapy types; ⚠️ NanoString COI
- TR-2026-06-04-011 / PMID 42236788 · Meta-Conformer-XAI ALL blood smear DL (Sci Rep) · 6/10 · Diagnostics · AUC-ROC >0.99 on public benchmarks; benchmark-only — no clinical validation
Novel Therapeutics
- TR-2026-06-04-013 / PMID 42234959 · TACI×CD3 bispecific antibody for BCMA-resistant MM (Blood Adv) · 6/10 · Drug Development · Novel target for BCMA-downregulation resistance; preclinical w/ primary patient cells
- TR-2026-06-04-014 / PMID 42236120 · PDPN/GD2 CAR T cell blend for heterogeneous GBM (J Immunother Cancer) · 6/10 · Treatment Innovation · Cure majority of mice with heterogeneous orthotopic tumors; PDO validation
- TR-2026-06-04-015 / PMID 42234933 · ICI resistance NSCLC — Lung-MAP perspective (J Clin Oncol) · 5/10 · Treatment Innovation · Expert perspective; no new primary data
Cardiovascular-Metabolic
- TR-2026-06-04-016 / PMID 42236297 · Empagliflozin vs dapagliflozin urogenital AEs — target trial emulation (DOM, n=86,432) · 6/10 · Prevention · Broadly similar safety profiles; small absolute RR differences
- TR-2026-06-04-017 / PMID 42236268 · Tirzepatide + metformin RCT in PCOS (DOM, n=60) · 6/10 · Treatment Innovation · -10.4 kg vs -1.7 kg; improved reproductive outcomes; underserved population
- TR-2026-06-04-018 / PMID 42236281 · HTE across 9 glucose-lowering drug classes (DOM, LEGEND-T2DM extension) · 5/10 · Precision Medicine · Limited HTE signals; hypothesis-generating only
Aging, Longevity
- TR-2026-06-04-019 / PMID 42234350 · Nutritional supplements for healthy aging (Curr Nutr Rep, 32 human studies) · 5/10 · Prevention · Protein/NAD+/glycine-NAC evidence; ⚠️ supplement industry COI
Rare Diseases
- TR-2026-06-04-020 / PMID 42235818 · Genotype-first diagnosis in rare disease — reversing diagnostic odyssey (Eur J Med Genet) · 5/10 · Genomics · VUS/reverse phenotyping framework; perspective piece
💡 UNSOLICITED FINDS
TR-2026-06-04-021 / PMID 42237053 · Robotic vs VATS vs Open Lobectomy for Lung Cancer: Multicenter Cohort · 6/10 🟢
J Robot Surg · Mazzali C, Russo AG et al. (8 Milan hospitals) · n=1605, IPW-adjusted · RATS vs VATS: fewer conversions (OR 2.47), shorter LOS; RATS vs OT: better adjusted OS (HR 1.51). Near-term implementable for thoracic surgery centers with robotic capacity.
📊 TODAY'S BREAKDOWN
By research category:
- Treatment Innovation: 7 | Diagnostics: 5 | Genomics/Precision Medicine: 5 | Early Detection: 3 | Prevention: 3 | Drug Development: 2 | Public Health: 2
By evidence maturity:
- Exploratory: 11 | Validated: 13 | Potentially Practice-Changing: 1 (PMID 42235013)
By watchlist topic (reviewed / kept / highest score):
| Topic | Reviewed | Kept | High Score |
|---|---|---|---|
| T1: Hematologic malignancies | 10 | 7 | 9 (NEJM AML) |
| T2: CBC/ML in hematology | 1 | 1 | 6 |
| T3: Early cancer detection | 10 | 3 | 8 (ctDNA gastric CA) |
| T4: AI/ML diagnostics | 10 | 3 | 7 (TNBC spatial) |
| T5: Precision oncology | 10 | 4 | 8 (Nat Cancer GBM) |
| T6: Novel therapeutics | 10 | 5 | 8 (Nat Biotechnol SSP) |
| T7: Cardiovascular-metabolic | 10 | 3 | 6 |
| T8: Aging/longevity | 2 | 1 | 5 |
| T9: Rare diseases | 8 | 2 | 5 |
| Sentinel | 10 | 1 | 6 |
By source type: peer_reviewed: 26 | preprint: 0
Topics with zero 8+ articles: T4 (AI/ML), T7 (Cardiovascular), T8 (Aging), T9 (Rare diseases)
🔧 RUN NOTES
T1 OUTSTANDING DAY: NEJM all-oral AML trial (PMID 42235013, score 9/10) is the strongest single find in weeks. Potentially practice-changing for elderly/unfit AML.
T2 (CBC/ML) chronic issue persists: Only 1 relevant result with improved query. Updated query per prior run recommendation performed better (no false positives) but volume remains near-zero. Recommendation for next run: Split T2 into two sub-queries: (a) CBC + ML/DL, (b) blood cell morphology + AI. Consider dropping the MeSH filter entirely.
T4 (AI/ML) volume problem: 189 raw results. Top 10 reviewed; most are engineering studies applied to clinical data with no clinical validation. Recommendation: Add
AND (validation[tiab] OR multicenter[tiab] OR "prospective"[tiab])to filter for clinically validated AI studies.T8 (Aging) improved but low volume: 2 relevant results with updated query (aging[MeSH:noexp] + biological aging[tiab] + cellular senescence[MeSH] + humans[MeSH]). Both were genuine aging-relevant papers (vs prior runs with insect/animal false positives). Recommendation next run: Add
OR telomere[tiab] OR "epigenome"[tiab] OR "inflammaging"[tiab].T5 + T6 both hit HIGH today: Nat Cancer GBM ICB (T5) and Nat Biotechnol SSP (T5/T6 crossover). High-signal day for precision oncology/immunotherapy space.
Conflict of interest flags today:
- PMID 42235013: Taiho Oncology (funder + 5 authors)
- PMID 42236297: Guardant Health (first and several co-authors)
- PMID 42237053: Nosotti: Fondazione IRCCS Ca' Granda
- PMID 42236165: Takeda Pharmaceuticals (multiple authors)
- PMID 42236117: NanoString Technologies (authors)
- PMID 42236958: Nolan/Goltsev: Akoya Biosciences equity
Rolling 7-day view (from state): T8 has produced 0 relevant articles for ≥4 consecutive runs. T2 produced 0 relevant articles for ≥3 consecutive runs (today: 1, but borderline). Query refinement is now the limiting factor — topics are genuinely sparse in daily windows, not query failures.
Window mode: INCREMENTAL (no expansion triggered — >5 relevant records found across all topics).